Tempest Therapeutics Inc. (TPST) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Tempest Therapeutics Inc.

    NASDAQ: TPST · Real-Time Price · USD
    10.99
    0.96 (9.63%)
    At close: Sep 05, 2025, 3:59 PM
    10.99
    0.00%
    Pre-market: Sep 08, 2025, 06:09 AM EDT

    Tempest Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 389K 381K n/a n/a
    Gross Profit
    		 -389K -381K -1.81M -1.27M
    Operating Income
    		 -42.03M -29.16M -34.64M -26.99M
    Interest Income
    		 1.5M 1.11M 549K 1.28K
    Pretax Income
    		 -41.84M -29.49M -35.71M -28.3M
    Net Income
    		 -41.84M -29.49M -35.71M -28.3M
    Selling & General & Admin
    		 13.55M 11.66M 12.11M 9.82M
    Research & Development
    		 28.48M 17.5M 22.53M 17.17M
    Other Expenses
    		 -389K n/a n/a -34K
    Operating Expenses
    		 41.64M 28.78M 34.64M 26.99M
    Interest Expense
    		 1.32M 1.45M 1.62M 1.28M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 42.03M 29.16M 34.64M 26.99M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 27.9M 15.42M 888K 291K
    Shares Outstanding (Diluted)
    		 27.9M 15.42M 888.38K 291.56K
    EPS (Basic)
    		 -1.5 -1.91 -3.18 -7.8
    EPS (Diluted)
    		 -1.5 -1.91 -3.18 -7.8
    EBITDA
    		 -40.14M -28.78M -32.28M -25.72M
    EBIT
    		 -40.53M -29.16M -34.09M -26.99M
    Depreciation & Amortization
    		 389K 381K 1.81M 1.27M

    Add to Watchlist